|
Mr. Jasuja joined MDB Capital Group in 2004 to lead its life sciences research effort, bringing both a medical background as well as extensive institutional equity research experience. Prior to joining MDB Capital Group, Mr. Jasuja served as Senior Biotechnology Research Analyst SOMA Partners LLC (formerly Techvest, LLC) and Sagient Research Systems. His past experience includes positions as Senior Biotechnology Research Analyst for the New York investment banking firm of Rodman & Renshaw. He has conducted equity research, due-diligence and consulting for institutional investors in a wide range of areas in molecular medicine, including immunotherapy, autoimmunity/inflammation, metabolic diseases, oncology, cardiology, ophthalmology, regenerative medicine and tissue engineering. Mr. Jasuja received his scientific training in immunology at Tufts Medical School and Harvard Medical School. He has conducted research in the areas of cell signaling, cancer biology, T-lymphocyte adhesion and activation, and macrophage arachidonic acid metabolism. At Tufts Medical School, he taught and supervised medical and dental students in the field of immunology. Mr. Jasuja received his B.Sc. from St. Xavier’s College, Bombay (India), his M.S. in Microbiology & Molecular Biology from the University of Montana and his Ph.D. in Immunology from Tufts Medical School in Boston. | 